Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies

European Heart Journal

Volumn 25, Issue 1, 2004, Pages 10-16

  Hanefeld, M ^a   Cagatay, M ^b   Petrowitsch, T ^b   Neuser, D ^b   Petzinna, D ^b   Rupp, M ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b BAYER AG   (Germany)

Author keywords

Acarbose; Cardiovascular events; Meta analysis; Myocardial infarction; Risk reduction; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; PLACEBO; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLATULENCE; GLYCEMIC INDEX; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; METABOLISM; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ACARBOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENZYME INHIBITORS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0346727578     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00468-8     Document Type: Article

References (35)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates, and projections. Diabetes Care 1995;21:1414-31.
2. Pyörälä K, Laakso M, Uusitopa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987;3:463-524.
3. Haffner SM, Letho S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-34.
4. Miettinen H, Lehto S, Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998;21:69-75.
5. Malmberg K, Yusuf S, Gerstein HC et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-q-wave myocardial infarction. Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102:1014-9.
6. UKPDS Group. Intensive blood control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
7. UKPDS Group. Intensive blood control with sulfonyl-ureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
8. Coutinho M, Gerstein HC, Wang Y et al. The relationship between glucose and incident cardiovascular events. A meta regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40.
9. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83.
10. Barrett-Connor E, Ferrara A. Isolated post challenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study. Diabetes Care 1998;21:1236-9.
11. Kawamori R. Asymptomatic hyperglycaemia and early atheroscleotic changes. Diabetes Res Clin Pract 1998;40(Suppl):S35-42.
12. Temelkova-Kurktschiev TS, Koehler C, Henkel E et al. Post challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000;23:1830-4.
13. The DECODE Study Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-404.
14. Laube H. Acarbose. An update of its therapeutic use in diabetes treatment. Clin Drug Invest 2002;22:141-56.
15. Hasche H, Mertes G, Bruns C et al. Effects of acarbose treatment in type 2 diabetic patients under dietary training. A multicentre, double-blind, placebo-controlled, 2-year study. Diabetes Nutr Metab 1999;12:277-85.
16. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res Clin Pract 2001;52:193-204.
17. Chiasson J-L, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus. The STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
18. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: The Essen-II Study. Am J Med 1997;103:483-90.
19. Kado S, Murakami T, Aoki A et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 1998;41:49-55.
20. Ceriello A, Taboga C, Tonutti L et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996;39:469-73.
21. Rosenthal JH, Mauersberger H. Effects on blood pressure of the (α-glucosidase inhibitor acarbose compared with the insulin enhancer glibenciamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest 2002;22:695-701.
22. Ceriello A. The post-prandial state and cardiovascular disease: relevance to diabetes mellitus. Diabetes Metab Res Rev 2000;16:125-32.
23. Lebovitz HE. Effect of the postprandial state on nontraditional risk factors. Am J Cardiol 2001;88(Suppl):20H-5H.
24. Chiasson J-L, Josse RG, Gomis R et al. Acarbose treatment reduces the risk of cardiovascular disease and hypertension in subjects with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 2003;290:486-94.
25. Pyörälä K, Pedersen TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
26. Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998;98:2513-9.
27. Fontbonne A, Eschwege E, Cambien F et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32:300-4.
28. Stamler J, Vaccaro O, Neaton JD et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention trial. Diabetes Care 1993;16:434-44.
29. Turner RC, Millns H, Neil HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8.
30. Cho E, Manson JE, Stampfer MJ et al. A prospective study of obesity and risk of coronary heart disease among diabetic women. Diabetes Care 2002;25:1142-8.
31. Puls W. Pharmacology of glucosidase inhibitors. In: Kuhlmann J, Puls W, editors. Oral Antidiabetics. Berlin: Springer Verlag; 1996, p. 497-538.
32. Chiasson J-L, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 1994;121:928-35.
33. Campbell I, Robertson-Mackay F, Streets E et al. Maintenance of glycaemic control with acarbose in diet treated type 2 diabetic patients. Diabetic Med 1998;15(Suppl 2):S29-30.
34. Holman R, Robertson-Mackay F, Gibbons F et al. Acarbose maintains glycaemic control in diet treated type 2 diabetes. Clin Sci 1999;96:7p.
35. Josse RG, Chiasson J-L, Ryan EA et al. Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Res Clin Pract 2003;59:37-42.